Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: A randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer - CALGB 40302 (alliance) Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Estradiol
  • Quinazolines

abstract

  • Adding lapatinib to fulvestrant does not improve PFS or OS in advanced ER-positive breast cancer and is more toxic.

publication date

  • December 10, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4251959

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.56.7941

PubMed ID

  • 25348000

Additional Document Info

start page

  • 3959

end page

  • 66

volume

  • 32

number

  • 35